Form 8-K - Current report:
SEC Accession No. 0001682852-24-000052
Filing Date
2024-10-02
Accepted
2024-10-02 07:03:59
Documents
14
Period of Report
2024-09-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mrna-20240928.htm   iXBRL 8-K 32564
2 EX-99.1 exhibit991-1022024.htm EX-99.1 9001
  Complete submission text file 0001682852-24-000052.txt   169010

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrna-20240928.xsd EX-101.SCH 1907
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrna-20240928_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrna-20240928_pre.xml EX-101.PRE 12512
16 EXTRACTED XBRL INSTANCE DOCUMENT mrna-20240928_htm.xml XML 2706
Mailing Address 325 BINNEY STREET CAMBRIDGE MA 02142
Business Address 325 BINNEY STREET CAMBRIDGE MA 02142 6177146500
Moderna, Inc. (Filer) CIK: 0001682852 (see all company filings)

EIN.: 813467528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38753 | Film No.: 241345260
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)